Cite
HARVARD Citation
Vo, A. et al. (2015). A Phase I/II Trial of the Interleukin-6 Receptor–Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients. Transplantation. 99 (11), p. . [Online].